Merck receives positive EU CHMP opinion for Keytruda as adjuvant treatment for cell lung cancer
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
First and only PARP inhibitor to improve invasive disease-free survival in patients
Subscribe To Our Newsletter & Stay Updated